What is the toxic dose of bupivacaine in adults?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 20, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Toxic Dose of Bupivacaine in Adults

The toxic threshold for bupivacaine begins at approximately 1.6 mg/kg IV, though severe cardiovascular collapse has been documented at doses as low as 1.1 mg/kg, making the maximum safe dose for regional anesthesia 2.5 mg/kg (or 3 mg/kg with epinephrine 1:200,000). 1, 2, 3

Understanding Toxic vs. Maximum Safe Dosing

The distinction between "toxic dose" and "maximum safe dose" is critical for clinical practice:

  • Documented toxicity threshold: Cardiovascular collapse, bradyasystolic arrest, and shock have occurred at IV doses as low as 1.1 mg/kg in adults, establishing this as the lower boundary of documented severe toxicity 3
  • Traditional toxic threshold: The previously accepted minimum IV dose associated with significant toxicity was 1.6 mg/kg 3
  • Maximum safe dose for regional anesthesia: 2.5 mg/kg for plain bupivacaine solutions, or up to 3 mg/kg (maximum 225 mg total) when combined with epinephrine 1:200,000 1, 2

Clinical Manifestations of Toxicity

Cardiovascular toxicity is the most dangerous manifestation and can occur with or without preceding CNS symptoms:

  • Cardiac effects: Dysrhythmias, severe hypotension, depression of cardiac output, bradyasystolic arrest, and cardiovascular collapse 3
  • CNS effects: May be absent even with severe cardiovascular toxicity, though typical early signs include altered consciousness, muscular tone changes, and seizures 3, 4

Route-Dependent Risk Stratification

The risk of toxicity varies dramatically by administration route and technique:

  • Highest risk (intravascular injection): Even doses well below 2.5 mg/kg can cause severe toxicity if inadvertently injected IV 3, 5
  • High absorption zones: Maximum dose should be reduced to approximately 75 mg (roughly 1 mg/kg in a 70 kg adult) 5
  • Standard peripheral nerve blocks: 2.5 mg/kg maximum (150 mg for most adults) 1, 2, 5
  • Protracted injection techniques: Up to 200 mg may be acceptable with catheter techniques 5

Critical Safety Considerations

Always calculate weight-based dosing and never exceed 2.5 mg/kg total dose regardless of technique to avoid systemic toxicity including cardiovascular collapse 1, 2:

  • For a 70 kg adult: Maximum 175 mg (70 mL of 0.25% solution) 2
  • With epinephrine 1:200,000: Maximum can increase to 3 mg/kg (210 mg in 70 kg adult), but total epinephrine must not exceed 0.25 mg 1, 5

Common Pitfalls to Avoid

  • Bilateral blocks: When performing bilateral procedures (e.g., TAP blocks), the total dose for both sides combined must stay under the maximum safe dose 2
  • Inadvertent intravascular injection: This is the most dangerous scenario—even "safe" doses become toxic when injected IV 3, 5
  • High absorption sites: Intercostal blocks, paracervical blocks, and other highly vascular areas require dose reduction 5

Safer Alternatives When Higher Volumes Needed

If larger volumes are required for adequate coverage:

  • Ropivacaine 0.2%: Allows up to 3 mg/kg (1.5 mL/kg), providing 50% more volume with potentially improved cardiac safety profile 1, 2
  • Levobupivacaine 0.25%: Same 2.5 mg/kg maximum but with reduced cardiac toxicity risk compared to racemic bupivacaine 1, 2

Special Populations

Infants and patients with low alpha-1 acid glycoprotein are at higher risk:

  • Toxicity has been documented at plasma levels of 0.56-1.62 μg/mL in awake infants, well below traditional toxic thresholds 4
  • Low protein binding increases free (active) drug concentration even at lower total plasma levels 4

References

Guideline

Dosis de Bupivacaína

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Safe Dosing of Bupivacaine 0.25%

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Cardiovascular collapse from low dose bupivacaine.

The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique, 2005

Research

[Local anesthetics--maximum recommended doses].

Anaesthesiologie und Reanimation, 1997

Related Questions

What is the safest dose of bupivacaine (local anesthetic)?
What is the recommended dose of bupivacaine (local anesthetic) based on weight?
What is the minimum time interval to repeat bupivacaine (local anesthetic) 2 milligrams/kilogram (mg/kg) for regional anesthesia?
What are the adverse effects, risk factors, and management strategies for bupivacaine toxicity?
What is the antidote for intra-arterial injection of bupivacaine (local anesthetic) or lidocaine (xylocaine) during a brachial block?
What is the differential diagnosis for this case?
Is a contrast‑enhanced computed tomography (CT) scan required when two neck ultrasounds show a suspicious lymph node versus a possible parathyroid adenoma in a patient with primary hyperparathyroidism?
What is the step‑by‑step emergency management of status epilepticus, including airway protection, benzodiazepine dosing, second‑line antiepileptic agents, and refractory treatment, for a pediatric patient?
What is the maximum recommended daily dose of rosuvastatin for a patient with chronic kidney disease stage 3b (estimated glomerular filtration rate 30–44 mL/min/1.73 m²)?
In a patient with primary hyperparathyroidism and a suspicious neck lesion confirmed as a parathyroid adenoma, is the adenoma typically benign?
How should I format a complete patient case sheet covering demographics, chief complaint, history of present illness, past medical/surgical/obstetric history, medications, allergies, family and social history, review of systems, physical examination, investigations, assessment, and management plan?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.